INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6001, 5097, 'Arformoterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6002, 5105, 'Arformoterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6003, 8100, 'Arformoterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6004, 14533, 'Arformoterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6005, 15524, 'Arformoterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6006, 19320, 'Arformoterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6007, 19322, 'Arformoterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6008, 30108, 'Arformoterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6009, 5097, 'Arformoterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6010, 5105, 'Arformoterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6011, 8100, 'Arformoterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6012, 14533, 'Arformoterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6013, 15524, 'Arformoterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6014, 19320, 'Arformoterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6015, 19322, 'Arformoterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6016, 30108, 'Arformoterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6017, 5097, 'Arformoterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6018, 5105, 'Arformoterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6019, 8100, 'Arformoterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6020, 14533, 'Arformoterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6021, 15524, 'Arformoterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6022, 19320, 'Arformoterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6023, 19322, 'Arformoterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6024, 30108, 'Arformoterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6025, 8073, 'Metaxalone', 'Anemia', 'The manufacturer considers the use of metaxalone to be contraindicated in patients with or predisposed to drug-induced, hemolytic, or other anemias.  Rare incidences of hemolytic anemia have been associated with the administration of metaxalone.', '3', '"Product Information. Skelaxin (metaxalone)." Carnrick Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6026, 26426, 'Metaxalone', 'Anemia', 'The manufacturer considers the use of metaxalone to be contraindicated in patients with or predisposed to drug-induced, hemolytic, or other anemias.  Rare incidences of hemolytic anemia have been associated with the administration of metaxalone.', '3', '"Product Information. Skelaxin (metaxalone)." Carnrick Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6027, 8073, 'Metaxalone', 'Liver Diseases', 'The manufacturer considers the use of metaxalone to be contraindicated in patients with severely impaired hepatic and/or renal function.  Metaxalone is metabolized by the liver and subsequently eliminated by the kidney, thus both parent drug and metabolites may accumulate in such patients.  Additionally, metaxalone may be hepatotoxic.  Jaundice as well as abnormalities in liver function tests, including elevations in serum AST, ALT, alkaline phosphatase and bilirubin, have been reported.  Nephrotoxicity and proteinuria have also occurred rarely.  Therapy with metaxalone should be administered cautiously in patients with mild to moderate hepatic and/or renal impairment.', '3', '"Product Information. Skelaxin (metaxalone)." Carnrick Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6028, 26426, 'Metaxalone', 'Liver Diseases', 'The manufacturer considers the use of metaxalone to be contraindicated in patients with severely impaired hepatic and/or renal function.  Metaxalone is metabolized by the liver and subsequently eliminated by the kidney, thus both parent drug and metabolites may accumulate in such patients.  Additionally, metaxalone may be hepatotoxic.  Jaundice as well as abnormalities in liver function tests, including elevations in serum AST, ALT, alkaline phosphatase and bilirubin, have been reported.  Nephrotoxicity and proteinuria have also occurred rarely.  Therapy with metaxalone should be administered cautiously in patients with mild to moderate hepatic and/or renal impairment.', '3', '"Product Information. Skelaxin (metaxalone)." Carnrick Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6029, 0, 'Methazolamide', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', 'Keisu M, Wiholm BE, Ost A, Mortimer O "Acetazolamide-associated aplastic anaemia." J Intern Med 228 (1990):  627-32|Gangitano JL, Foster SH, Contro RM "Nonfatal methazolamide-induced aplastic anemia." Am J Ophthalmol 86 (1978):  138-9|Wisch N, Fischbein FI, Siegel R, Glass JL, Leopold I "Aplastic anemia resulting from the use of carbonic anhydrase inhibitors." Am J Ophthalmol 75 (1973):  130-2|Lubeck MJ "Aplastic anemia following acetazolamide therapy." Am J Ophthalmol 69 (1970):  684-5|Kristinsson A "Fatal reaction to acetazolamide." Br J Ophthalmol 51 (1967):  348-9|Englund GW "Fatal pancytopenia and acetazolamide therapy." JAMA 210 (1969):  2282|Rentiers PK, Johnston AC, Buskard N "Severe aplastic anemia as a complication of acetazolamide therapy." Can J Ophthalmol 5 (1970):  337-42|McWhae JA, Chang J, Lipton JH "Drug-induced fatal aplastic anemia following cataract surgery." Can J Ophthalmol 27 (1992):  313-5|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6030, 0, 'Methazolamide', 'Adrenal Insufficiency', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with adrenal insufficiency.  The carbonic anhydrase inhibitor effect may exacerbate electrolyte problems that can occur with primary adrenal insufficiency.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered to these patients.  Monitoring electrolyte levels is recommended.', '3', '"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6031, 0, 'Methazolamide', 'Glaucoma, Angle-Closure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with closed-angle glaucoma.  Carbonic anhydrase inhibitors may mask worsening glaucoma due to decreased intraocular pressure.  Extreme caution should be exercised if carbonic anhydrase inhibitors is administered to these patients.', '3', 'Fan JT, Johnson DH, Burk RR "Transient myopia, angle-closure glaucoma, and choroidal detachment after oral acetazolamide." Am J Ophthalmol 115 (1993):  813-4|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6032, 0, 'Methazolamide', 'Hypokalemia', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with hypokalemia .  Carbonic anhydrase inhibitors may cause increased potassium excretion.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.', '3', 'Torres CF, Griggs RC, Moxley RT, Bender AN "Hypokalemic periodic paralysis exacerbated by acetazolamide." Neurology 31 (1981):  1423-8|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6033, 0, 'Methazolamide', 'Hyponatremia', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with hyponatremia .  Carbonic anhydrase inhibitors may cause sodium excretion.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.', '3', '"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6034, 0, 'Methazolamide', 'Kidney Diseases', 'The use of some carbonic anhydrase inhibitors is contraindicated in patients with severe kidney disease.  Dysuria, crystalluria, renal colic, and other renal lesions have been reported during therapy with carbonic anhydrase inhibitors.', '3', 'Hannedouche T, Lazaro M, Delgado AG, Boitard C, Lacour B, Grunfeld JP "Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients." Clin Sci 81 (1991):  457-64|Reid W, Harrower AD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  1114|Goodfield M, Davis J, Jeffcoate W "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  422|Maisey DN, Brown RD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure." Br Med J (Clin Res Ed) 283 (1981):  1527-8|De Marchi S, Cecchin E "Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis." Clin Sci 78 (1990):  295-302|Korzets A, Gafter U, Floru S, Chagnac A, Zevin D "Deteriorating renal function with acetazolamide in a renal transplant patient with pseudotumor cerebri." Am J Kidney Dis 21 (1993):  322-4|Parfitt AM "Acetazolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis: relationship to citrate and calcium excretion." Arch Intern Med 124 (1969):  736-40|Tawil R, Moxley RT 3d, Griggs RC "Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders." Neurology 43 (1993):  1105-6|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|Parikh JR, Nolan RL, Bannerjee A, Gault MH "Acetazolamide-associated nephrocalcinosis in a transplant kidney." Transplantation 59 (1995):  1742-3|Schwenk MH, Stpeter WL, Meese MG, Singhal PC "Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis." Pharmacotherapy 15 (1995):  522-7|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6035, 0, 'Methazolamide', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', 'Maren TH "Acetazolamide and advanced liver disease ." Am J Ophthalmol 102 (1986):  672-3|Margo CE "Acetazolamide and advanced liver disease." Am J Ophthalmol 101 (1986):  611-2|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6036, 0, 'Methazolamide', 'Acidosis, Respiratory', 'Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels.  Respiratory acidosis may be precipitated or increased in these patients.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis.  Respiratory status should be monitored during therapy.', '2', 'Watson WA, Garrelts JC, Zinn PD, Garriott JC, McLemore TL, Clementi WA "Chronic acetazolamide intoxication." J Toxicol Clin Toxicol 22 549-63|Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979):  284-6|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6037, 0, 'Methazolamide', 'Diabetes Mellitus', 'Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus.  Routine glucose monitoring is recommended during therapy.', '2', 'Hannedouche T, Lazaro M, Delgado AG, Boitard C, Lacour B, Grunfeld JP "Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients." Clin Sci 81 (1991):  457-64|Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979):  284-6|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6038, 0, 'Methazolamide', 'Gout', 'Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout.  Elevated serum uric acid levels return to normal when the drug is discontinued.  Monitoring of uric acid levels is recommended in these patients.', '2', 'Ferry AP, Lichtig M "Gouty arthritis as a complication of acetazolamide (diamox) therapy for glaucoma." Can J Ophthalmol 4 (1969):  145-7|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6039, 0, 'Methazolamide', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', 'Reid W, Harrower AD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  1114|Goodfield M, Davis J, Jeffcoate W "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  422|Maisey DN, Brown RD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure." Br Med J (Clin Res Ed) 283 (1981):  1527-8|Watson WA, Garrelts JC, Zinn PD, Garriott JC, McLemore TL, Clementi WA "Chronic acetazolamide intoxication." J Toxicol Clin Toxicol 22 549-63|Heller I, Halevy J, Cohen S, Theodor E "Significant metabolic acidosis induced by acetazolamide: not a rare complication." Arch Intern Med 145 (1985):  1815-7|Gabay EL "Metabolic acidosis from acetazolamide therapy ." Arch Ophthalmol 101 (1983):  303-4|Berthelsen P "Cardiovascular performance and oxyhemoglobin dissociation after acetazolamide in metabolic alkalosis." Intensive Care Med 8 (1982):  269-74|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6040, 614, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6041, 2576, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6042, 2577, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6043, 2578, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6044, 2579, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6045, 3606, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6046, 3607, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6047, 3608, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6048, 4684, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6049, 5600, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6050, 5601, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6051, 5607, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6052, 5608, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6053, 5609, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6054, 5610, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6055, 8006, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6056, 8082, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6057, 13130, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6058, 13692, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6059, 14125, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6060, 16319, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6061, 17997, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6062, 21147, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6063, 22409, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6064, 22485, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6065, 22574, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6066, 22575, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6067, 22635, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6068, 33194, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6069, 33195, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6070, 33196, 'Metformin', 'Acidosis, Lactic', 'The use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.  Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL.  Metformin should also not be administered to patients with acute or chronic metabolic acidosis.  In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.  All patients treated with metformin should have renal function monitored regularly (at least annually or more frequently if necessary) and be advised of the significance of nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and gastrointestinal disturbances that arise after stabilization of metformin dosage.  More marked acidosis may be associated with hypothermia, hypotension, and resistant bradyarrhythmias.  Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified.  If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.', '3', 'Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G "Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis." Arch Intern Med 144 (1984):  203-5|Biron P "Metformin monitoring." Can Med Assoc J 123 (1980):  11-2|Ryder RE "Lactic acidotic coma with multiple medication including metformin in a patient with normal renal function." Br J Clin Pract 38 (1984):  229-30,232|Luft D, Schmulling RM, Eggstein M "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases." Diabetologia 14 (1978):  75-87|Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR "Metformin-induced lactic acidosis in the presence of acute renal failure." Diabetologia 13 (1977):  211-7|Wiholm BE, Myrhed M "Metformin-associated lactic acidosis in Sweden 1977-1991." Eur J Clin Pharmacol 44 (1993):  589-91|Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J "Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination." Int J Clin Pharmacol Ther Toxicol 27 (1989):  285-8|Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J "Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin." Intensive Care Med 13 (1987):  383-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  541-9|Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 333 (1995):  550-4|Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG "Kidney function and age are both predictors of pharmacokinetics of metformin." J Clin Pharmacol 35 (1995):  1094-102|Gueriguian J, Green L, Misbin RI, Stadel B, Fleming GA "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269|De Fronzo RA, Goodman AM "Efficacy of metformin in non-insulin dependent diabetes mellitus." N Engl J Med 334 (1996):  269-70|Deutsch JC, Santhoshkumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269|Bailey CJ, Path MR, Turner RC "Metformin." N Engl J Med 334 (1996):  574-9|Pearlman BL, Fenves AZ, Emmett M "Metformin-associated lactic acidosis." Am J Med 101 (1996):  109-10|Lustik SJ, Vogt A, Chhibber AK "Postoperative lactic acidosis in patients receiving metformin." Anesthesiology 89 (1998):  266-7|Lalau JD, Mourlhon C, Bergeret A, Lacroix C "Consequences of metformin intoxication." Diabetes Care 21 (1998):  2036-7|Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA "Lactic acidosis in patients with diabetes treated with metformin." N Engl J Med 338 (1998):  265-6|Stang M, Wysowski DK, ButlerJones D "Incidence of lactic acidosis in metformin users." Diabetes Care 22 (1999):  925-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6071, 614, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6072, 2576, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6073, 2577, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6074, 2578, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6075, 2579, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6076, 3606, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6077, 3607, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6078, 3608, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6079, 4684, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6080, 5600, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6081, 5601, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6082, 5607, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6083, 5608, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6084, 5609, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6085, 5610, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6086, 8006, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6087, 8082, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6088, 13130, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6089, 13692, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6090, 14125, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6091, 16319, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6092, 17997, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6093, 21147, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6094, 22409, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6095, 22485, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6096, 22574, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6097, 22575, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6098, 22635, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6099, 33194, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6100, 33195, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6101, 33196, 'Metformin', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6102, 614, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6103, 2576, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6104, 2577, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6105, 2578, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6106, 2579, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6107, 3606, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6108, 3607, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6109, 3608, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6110, 4684, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6111, 5600, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6112, 5601, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6113, 5607, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6114, 5608, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6115, 5609, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6116, 5610, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6117, 8006, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6118, 8082, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6119, 13130, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6120, 13692, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6121, 14125, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6122, 16319, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6123, 17997, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6124, 21147, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6125, 22409, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6126, 22485, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6127, 22574, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6128, 22575, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6129, 22635, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6130, 33194, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6131, 33195, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6132, 33196, 'Metformin', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6133, 614, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6134, 2576, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6135, 2577, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6136, 2578, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6137, 2579, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6138, 3606, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6139, 3607, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6140, 3608, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6141, 4684, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6142, 5600, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6143, 5601, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6144, 5607, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6145, 5608, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6146, 5609, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6147, 5610, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6148, 8006, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6149, 8082, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6150, 13130, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6151, 13692, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6152, 14125, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6153, 16319, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6154, 17997, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6155, 21147, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6156, 22409, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6157, 22485, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6158, 22574, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6159, 22575, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6160, 22635, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6161, 33194, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6162, 33195, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6163, 33196, 'Metformin', 'Vitamin B 12 Deficiency', 'Metformin may interfere with vitamin B12 (cyanocobalamin) absorption from the B12-intrinsic factor complex.  A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials.  Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency.  Vitamin B12 supplementation as well as annual measurements of hematologic parameters may be appropriate.', '2', 'Tomkin GH "Metformin and B 12 malabsorption." Ann Intern Med 76 (1972):  668|Callaghan TS, Hadden DR, Tomkin GH "Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment." Br Med J 280 (1980):  1214-5|Stowers JM, Smith OA "Vitamin B 12 and metformin." Br Med J 3 (1971):  246-7|Tomkin GH, Hadden DR, Weaver JA, Montgomery DA "Vitamin-B12 status of patients on long-term metformin therapy." Br Med J 2 (1971):  685-7|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|Deutsch JC, Santhosh-Kumar CR, Kolhouse JF "Efficacy of metformin in non-insulin-dependent diabetes mellitus." N Engl J Med 334 (1996):  269', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6164, 0, 'Methenamine', 'Crystalluria', 'The use of methenamine salts (i.e. methenamine hippurate or mandelate), but not the base, is contraindicated in patients with severe renal impairment or dehydration.  Methenamine is excreted by the kidney and concentrated in the urine.  In patients with low urinary output, the salts can precipitate and cause crystalluria.', '3', 'Klinge E, Mannisto P, Mantyla R, Lamminsivu U, Ottoila P "Pharmacokinetics of methenamine in healthy volunteers." J Antimicrob Chemother 9 (1982):  209-16|Gleckman R, Alvarez S, Joubert D, Matthews S "Drug therapy reviews: methenamine mandelate and methenamine hippurate." Am J Hosp Pharm 36 (1979):  1509-12|Australian Drug Evaluation Committee "Adverse effects of drugs commonly used in the treatment of urinary tract infection." Med J Aust 1 (1972):  435-8|"Product Information. Hiprex (methenamine)." Hoechst Marion Roussel  (2002):|"Product Information. Mandelamine (methenamine)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6165, 0, 'Methenamine', 'Gout', 'Methenamine mandelate (salts), should be avoided in patients with gout as it may precipitate urate crystals in their urine.  A similar situation may arise in patients with a predisposition to the formation of uric acid stones.', '3', '"Product Information. Hiprex (methenamine)." Hoechst Marion Roussel  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6166, 0, 'Methenamine', 'Liver Diseases', 'The use of methenamine and its salts (i.e. methenamine hippurate or mandelate) is contraindicated in patients with severe hepatic impairment.  Methenamine is hydrolyzed to ammonia and formaldehyde in the urine under acidic conditions.  Patients with liver disease may already have elevated ammonia levels, which can cause or exacerbate hepatic encephalopathy.  Methenamine hippurate has also been associated with isolated cases of transient elevations in serum transaminases.  The manufacturer recommends periodic liver function tests during therapy, particularly in patients with preexisting liver dysfunction.', '3', 'Strom J, Jun H "Kinetics of hydrolysis of methenamine." Pharm Bull 23 (1975):  651|Gleckman R, Alvarez S, Joubert D, Matthews S "Drug therapy reviews: methenamine mandelate and methenamine hippurate." Am J Hosp Pharm 36 (1979):  1509-12|"Product Information. Hiprex (methenamine)." Hoechst Marion Roussel  (2002):|"Product Information. Mandelamine (methenamine)." Parke-Davis  (2002):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6167, 0, 'Methadone', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6168, 0, 'Methadone', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6169, 0, 'Methadone', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6170, 0, 'Methadone', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6171, 0, 'Methadone', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6172, 0, 'Methadone', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6173, 0, 'Methadone', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6174, 0, 'Methadone', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6175, 0, 'Methadone', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6176, 0, 'Methadone', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6177, 0, 'Methadone', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6178, 0, 'Methadone', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6179, 0, 'Methadone', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6180, 0, 'Methadone', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6181, 0, 'Methadone', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6182, 0, 'Methadone', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6183, 0, 'Methadone', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6184, 0, 'Argatroban', 'Hemorrhage', 'The use of thrombin inhibitors is contraindicated in the presence of active major bleeding.  Additionally, these drugs should be used with caution in patients with disease states associated with an increased risk of bleeding.', '3', '"Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim  (2010):|"Product Information. Bivalirudin (bivalirudin)." Fresenius Kabi USA, LLC  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6185, 0, 'Methimazole', 'Hematologic Diseases', 'The use of thioamide antithyroid agents may infrequently be associated with the development of blood dyscrasias, primarily agranulocytosis but also leukopenia, thrombocytopenia, and aplastic anemia.  Most cases of agranulocytosis occur within the first two months of therapy, with incidence declining gradually thereafter.  Patients older than 40 years of age and those receiving more than 40 mg/day of methimazole appear to be at substantially increased risk (a dosage association has not been reported for propylthiouracil).  Therapy with thioamide derivatives should be administered cautiously in patients with or predisposed to blood dyscrasias and/or bone marrow depression.  Clinical monitoring of hematopoietic function is recommended, with particular focus on leukocyte and differential counts.  Because leukopenia (i.e. leukocyte count < 4000/mm3) may also occur in 10% of patients with untreated hyperthyroidism and is often associated with relative granulocytopenia, baseline count should be determined prior to initiating antithyroid medication.  Patients should be instructed to immediately report during therapy any signs or symptoms suggestive of myelosuppression such as fever, sore throat, local infection, easy bruising, or bleeding.  Cessation of antithyroid drug and institution of appropriate supportive measures are necessary if agranulocytosis or aplastic anemia develops.', '3', 'Cooper DS "Antithyroid drugs." N Engl J Med 311 (1984):  1353-62|Biswas N, Ahn YH, Goldman JM, Schwartz JM "Aplastic anemia associated with antithyroid drugs." Am J Med Sci 301 (1991):  190-4|Valenta LJ, Elias AN, Weber DJ "Hyperthyroidism and propylthiouracil-induced agranulocytosis during chronic lithium carbonate therapy." Am J Psychiatry 138 (1981):  1605-7|Shambaugh GE, 3d  Khoury N, Zonschein J, Sizemore GW "Hypocalcemia accompanying agranulocytosis during propylthiouracil therapy." Ann Intern Med 91 (1979):  576-7|Tajiri J, Noguchi S, Murakami T, Murakami N "Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring." Arch Intern Med 150 (1990):  621-4|"Product Information. Propylthiouracil (propylthiouracil)." Lederle Laboratories  (2001):|Hoffman DM, Burgess J, Hill P "Agranulocytosis and hepatic dysfunction following propylthiouracil treatment." Aust N Z J Med 24 (1994):  409-10|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Bishara J, Cux S, Pitlik S "Methimazole-induced aplastic anemia." Ann Pharmacother 30 (1996):  684|"Product Information. Tapazole (methimazole)." King Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6186, 0, 'Methimazole', 'Liver Diseases', 'The use of thioamide antithyroid agents has been associated with hepatotoxic effects, including transient elevations of serum transaminases and, rarely, cholestatic jaundice, fulminant hepatitis, hepatic necrosis, encephalopathy and death.  Therapy with thioamide derivatives should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Treatment should be discontinued if deterioration in liver function or other signs of hepatic injury occur.  The jaundice associated with methimazole-induced hepatitis may persist for several weeks after withdrawal of the medication.', '3', 'Limaye A, Ruffolo PR "Propylthiouracil-induced fatal hepatic necrosis." Am J Gastroenterol 82 (1987):  152-4|Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ "Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study." Ann Intern Med 118 (1993):  424-8|Safani MM, Tatro DS, Rudd P "Fatal propylthiouracil-induced hepatitis ." Arch Intern Med 142 (1982):  838-9|Hanson JS "Propylthiouracil and hepatitis. Two cases and a review of the literature." Arch Intern Med 144 (1984):  994-6|Seidman DS, Livni E, Ilie B, Blum I "Propylthiouracil-induced cholestatic jaundice." J Toxicol Clin Toxicol 24 (1986):  353-60|"Product Information. Propylthiouracil (propylthiouracil)." Lederle Laboratories  (2001):|Hoffman DM, Burgess J, Hill P "Agranulocytosis and hepatic dysfunction following propylthiouracil treatment." Aust N Z J Med 24 (1994):  409-10|Westphal SA "Hepatotoxicity from propylthiouracil." South Med J 87 (1994):  943-7|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ozenirler S, Tuncer C, Boztepe U, Akyol G, Alkim H, Cakir N, Kandilci U "Propylthiouracil-induced hepatic damage." Ann Pharmacother 30 (1996):  960-3|Deidiker R, Demello DE "Propylthiouracil-induced fulminant hepatitis: case report and review of the literature." Pediatr Pathol Lab Med 16 (1996):  845-52|Hardee JT, Barnett AL, Thannoun A, Eghtesad B, Wheeler D, Jamal MM "Propylthiouracil-induced hepatotoxicity." West J Med 165 (1996):  144-7|"Product Information. Tapazole (methimazole)." King Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6187, 0, 'Methimazole', 'Hemorrhagic Disorders', 'Thioamide antithyroid agents may interfere with the action of vitamin K and have been reported in isolated cases to induce hypoprothombinemia and bleeding.  Myelosuppression rarely resulting in thrombocytopenia has also been reported.  Therapy with thioamide derivatives should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  Clinical monitoring of prothrombin time or INR is recommended.', '3', 'Sammon TJ, Peden VH, Witzleben C, King JP "Disseminated intravascular coagulation complicating propylthiouracil therapy. A case description of a 16-year-old girl." Clin Pediatr (Phila) 10 (1971):  739-42|"Product Information. Propylthiouracil (propylthiouracil)." Lederle Laboratories  (2001):|"Product Information. Tapazole (methimazole)." King Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6188, 566, 'Methocarbamol', 'Kidney Diseases', 'The injectable formulation of methocarbamol is contraindicated for use in patients with impaired renal function due to the nephrotoxic potential of polyethylene glycol (PEG) 300 present in the vehicle.  Quantities of PEG 300 much greater than that found in recommended doses of injectable methocarbamol have increased preexisting acidosis and urea retention in patients with renal impairment.', '3', '"Product Information. Robaxin (methocarbamol)." Whitehall-Robbins', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6189, 8088, 'Methocarbamol', 'Kidney Diseases', 'The injectable formulation of methocarbamol is contraindicated for use in patients with impaired renal function due to the nephrotoxic potential of polyethylene glycol (PEG) 300 present in the vehicle.  Quantities of PEG 300 much greater than that found in recommended doses of injectable methocarbamol have increased preexisting acidosis and urea retention in patients with renal impairment.', '3', '"Product Information. Robaxin (methocarbamol)." Whitehall-Robbins', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6190, 19132, 'Methocarbamol', 'Kidney Diseases', 'The injectable formulation of methocarbamol is contraindicated for use in patients with impaired renal function due to the nephrotoxic potential of polyethylene glycol (PEG) 300 present in the vehicle.  Quantities of PEG 300 much greater than that found in recommended doses of injectable methocarbamol have increased preexisting acidosis and urea retention in patients with renal impairment.', '3', '"Product Information. Robaxin (methocarbamol)." Whitehall-Robbins', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6191, 22639, 'Methocarbamol', 'Kidney Diseases', 'The injectable formulation of methocarbamol is contraindicated for use in patients with impaired renal function due to the nephrotoxic potential of polyethylene glycol (PEG) 300 present in the vehicle.  Quantities of PEG 300 much greater than that found in recommended doses of injectable methocarbamol have increased preexisting acidosis and urea retention in patients with renal impairment.', '3', '"Product Information. Robaxin (methocarbamol)." Whitehall-Robbins', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6192, 566, 'Methocarbamol', 'Seizures', 'Seizures have occurred during the intravenous administration of methocarbamol.  In some cases, the patient had a known history of epilepsy, and the psychic trauma of the procedure may have been a contributing factor.  Nevertheless, therapy with the injectable formulation of methocarbamol should be administered cautiously in patients with a history of epilepsy.', '2', '"Product Information. Robaxin (methocarbamol)." Whitehall-Robbins', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6193, 8088, 'Methocarbamol', 'Seizures', 'Seizures have occurred during the intravenous administration of methocarbamol.  In some cases, the patient had a known history of epilepsy, and the psychic trauma of the procedure may have been a contributing factor.  Nevertheless, therapy with the injectable formulation of methocarbamol should be administered cautiously in patients with a history of epilepsy.', '2', '"Product Information. Robaxin (methocarbamol)." Whitehall-Robbins', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6194, 19132, 'Methocarbamol', 'Seizures', 'Seizures have occurred during the intravenous administration of methocarbamol.  In some cases, the patient had a known history of epilepsy, and the psychic trauma of the procedure may have been a contributing factor.  Nevertheless, therapy with the injectable formulation of methocarbamol should be administered cautiously in patients with a history of epilepsy.', '2', '"Product Information. Robaxin (methocarbamol)." Whitehall-Robbins', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6195, 22639, 'Methocarbamol', 'Seizures', 'Seizures have occurred during the intravenous administration of methocarbamol.  In some cases, the patient had a known history of epilepsy, and the psychic trauma of the procedure may have been a contributing factor.  Nevertheless, therapy with the injectable formulation of methocarbamol should be administered cautiously in patients with a history of epilepsy.', '2', '"Product Information. Robaxin (methocarbamol)." Whitehall-Robbins', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6196, 8642, 'Methoxsalen', 'Aphakia', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with aphakia.  The potential for retinal damage with PUVA (psoralen and UVA photochemotherapy) may be increased due to the absence of lenses.', '3', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6197, 11875, 'Methoxsalen', 'Aphakia', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with aphakia.  The potential for retinal damage with PUVA (psoralen and UVA photochemotherapy) may be increased due to the absence of lenses.', '3', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6198, 23373, 'Methoxsalen', 'Aphakia', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with aphakia.  The potential for retinal damage with PUVA (psoralen and UVA photochemotherapy) may be increased due to the absence of lenses.', '3', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6199, 28696, 'Methoxsalen', 'Aphakia', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with aphakia.  The potential for retinal damage with PUVA (psoralen and UVA photochemotherapy) may be increased due to the absence of lenses.', '3', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6200, 8642, 'Methoxsalen', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6201, 11875, 'Methoxsalen', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6202, 23373, 'Methoxsalen', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6203, 28696, 'Methoxsalen', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6204, 8642, 'Methoxsalen', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6205, 11875, 'Methoxsalen', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6206, 23373, 'Methoxsalen', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6207, 28696, 'Methoxsalen', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6208, 8642, 'Methoxsalen', 'Heart Diseases', 'Patients with cardiac disease may not be able to tolerate prolonged standing or exposure to heat stress required of treatment in a vertical UVA chamber.  Therapy with methoxsalen, if used in patients with cardiac disease,  may require special precautions.', '2', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6209, 11875, 'Methoxsalen', 'Heart Diseases', 'Patients with cardiac disease may not be able to tolerate prolonged standing or exposure to heat stress required of treatment in a vertical UVA chamber.  Therapy with methoxsalen, if used in patients with cardiac disease,  may require special precautions.', '2', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6210, 23373, 'Methoxsalen', 'Heart Diseases', 'Patients with cardiac disease may not be able to tolerate prolonged standing or exposure to heat stress required of treatment in a vertical UVA chamber.  Therapy with methoxsalen, if used in patients with cardiac disease,  may require special precautions.', '2', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6211, 28696, 'Methoxsalen', 'Heart Diseases', 'Patients with cardiac disease may not be able to tolerate prolonged standing or exposure to heat stress required of treatment in a vertical UVA chamber.  Therapy with methoxsalen, if used in patients with cardiac disease,  may require special precautions.', '2', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6212, 8642, 'Methoxsalen', 'Liver Diseases', 'Patients with hepatic insufficiency should be treated with caution since hepatic biotransformation is necessary for drug urinary excretion.', '2', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6213, 11875, 'Methoxsalen', 'Liver Diseases', 'Patients with hepatic insufficiency should be treated with caution since hepatic biotransformation is necessary for drug urinary excretion.', '2', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6214, 23373, 'Methoxsalen', 'Liver Diseases', 'Patients with hepatic insufficiency should be treated with caution since hepatic biotransformation is necessary for drug urinary excretion.', '2', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6215, 28696, 'Methoxsalen', 'Liver Diseases', 'Patients with hepatic insufficiency should be treated with caution since hepatic biotransformation is necessary for drug urinary excretion.', '2', '"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6216, 8642, 'Methoxsalen', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6217, 11875, 'Methoxsalen', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6218, 23373, 'Methoxsalen', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6219, 28696, 'Methoxsalen', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6220, 5019, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6221, 8089, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6222, 11930, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6223, 14338, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6224, 14594, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6225, 18291, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6226, 22641, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6227, 22644, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6228, 22645, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6229, 22647, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6230, 22648, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6231, 22649, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6232, 22650, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6233, 22651, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6234, 22652, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6235, 22653, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6236, 22654, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6237, 22655, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6238, 22657, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6239, 22786, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6240, 23055, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6241, 23056, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6242, 28776, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6243, 28778, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6244, 28779, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6245, 32982, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6246, 32983, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6247, 33198, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6248, 5019, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6249, 8089, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6250, 11930, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6251, 14338, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6252, 14594, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6253, 18291, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6254, 22641, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6255, 22644, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6256, 22645, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6257, 22647, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6258, 22648, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6259, 22649, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6260, 22650, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6261, 22651, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6262, 22652, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6263, 22653, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6264, 22654, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6265, 22655, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6266, 22657, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6267, 22786, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6268, 23055, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6269, 23056, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6270, 28776, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6271, 28778, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6272, 28779, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6273, 32982, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6274, 32983, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6275, 33198, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6276, 5019, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6277, 8089, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6278, 11930, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6279, 14338, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6280, 14594, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6281, 18291, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6282, 22641, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6283, 22644, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6284, 22645, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6285, 22647, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6286, 22648, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6287, 22649, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6288, 22650, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6289, 22651, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6290, 22652, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6291, 22653, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6292, 22654, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6293, 22655, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6294, 22657, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6295, 22786, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6296, 23055, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6297, 23056, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6298, 28776, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6299, 28778, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6300, 28779, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6301, 32982, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6302, 32983, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6303, 33198, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6304, 5019, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6305, 8089, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6306, 11930, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6307, 14338, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6308, 14594, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6309, 18291, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6310, 22641, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6311, 22644, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6312, 22645, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6313, 22647, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6314, 22648, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6315, 22649, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6316, 22650, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6317, 22651, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6318, 22652, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6319, 22653, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6320, 22654, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6321, 22655, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6322, 22657, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6323, 22786, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6324, 23055, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6325, 23056, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6326, 28776, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6327, 28778, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6328, 28779, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6329, 32982, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6330, 32983, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6331, 33198, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6332, 5019, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6333, 8089, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6334, 11930, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6335, 14338, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6336, 14594, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6337, 18291, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6338, 22641, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6339, 22644, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6340, 22645, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6341, 22647, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6342, 22648, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6343, 22649, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6344, 22650, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6345, 22651, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6346, 22652, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6347, 22653, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6348, 22654, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6349, 22655, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6350, 22657, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6351, 22786, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6352, 23055, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6353, 23056, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6354, 28776, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6355, 28778, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6356, 28779, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6357, 32982, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6358, 32983, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6359, 33198, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '"Product Information. Rheumatrex (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6360, 8642, 'Methoxsalen (topical)', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6361, 11875, 'Methoxsalen (topical)', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6362, 23373, 'Methoxsalen (topical)', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6363, 28696, 'Methoxsalen (topical)', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6364, 8642, 'Methoxsalen (topical)', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6365, 11875, 'Methoxsalen (topical)', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6366, 23373, 'Methoxsalen (topical)', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6367, 28696, 'Methoxsalen (topical)', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6368, 8642, 'Methoxsalen (topical)', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6369, 11875, 'Methoxsalen (topical)', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6370, 23373, 'Methoxsalen (topical)', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6371, 28696, 'Methoxsalen (topical)', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '"Product Information. Oxsoralen (methoxsalen topical)." Apothecon Inc  (2022):|"Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6372, 17, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6373, 18, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6374, 20, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6375, 21, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6376, 22, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6377, 204, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6378, 205, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6379, 925, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6380, 927, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6381, 940, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6382, 943, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6383, 946, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6384, 948, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6385, 950, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6386, 952, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6387, 1766, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6388, 3339, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6389, 10222, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6390, 14308, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6391, 14309, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6392, 14310, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6393, 14311, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6394, 14392, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6395, 14393, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6396, 14394, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6397, 14400, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6398, 14401, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6399, 14404, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6400, 25140, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6401, 26610, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6402, 26614, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6403, 26615, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6404, 26616, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6405, 26617, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6406, 26618, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6407, 26619, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6408, 31991, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6409, 32347, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6410, 32440, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6411, 32441, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6412, 17, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6413, 18, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6414, 20, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6415, 21, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6416, 22, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6417, 204, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6418, 205, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6419, 925, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6420, 927, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6421, 940, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6422, 943, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6423, 946, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6424, 948, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6425, 950, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6426, 952, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6427, 1766, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6428, 3339, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6429, 10222, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6430, 14308, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6431, 14309, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6432, 14310, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6433, 14311, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6434, 14392, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6435, 14393, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6436, 14394, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6437, 14400, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6438, 14401, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6439, 14404, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6440, 25140, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6441, 26610, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6442, 26614, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6443, 26615, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6444, 26616, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6445, 26617, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6446, 26618, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6447, 26619, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6448, 31991, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6449, 32347, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6450, 32440, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6451, 32441, 'Aripiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6452, 17, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6453, 18, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6454, 20, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6455, 21, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6456, 22, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6457, 204, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6458, 205, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6459, 925, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6460, 927, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6461, 940, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6462, 943, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6463, 946, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6464, 948, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6465, 950, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6466, 952, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6467, 1766, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6468, 3339, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6469, 10222, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6470, 14308, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6471, 14309, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6472, 14310, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6473, 14311, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6474, 14392, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6475, 14393, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6476, 14394, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6477, 14400, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6478, 14401, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6479, 14404, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6480, 25140, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6481, 26610, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6482, 26614, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6483, 26615, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6484, 26616, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6485, 26617, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6486, 26618, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6487, 26619, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6488, 31991, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6489, 32347, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6490, 32440, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6491, 32441, 'Aripiprazole', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6492, 17, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6493, 18, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6494, 20, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6495, 21, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6496, 22, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6497, 204, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6498, 205, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6499, 925, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6500, 927, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6501, 940, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6502, 943, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6503, 946, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6504, 948, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6505, 950, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6506, 952, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6507, 1766, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6508, 3339, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6509, 10222, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6510, 14308, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6511, 14309, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6512, 14310, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6513, 14311, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6514, 14392, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6515, 14393, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6516, 14394, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6517, 14400, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6518, 14401, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6519, 14404, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6520, 25140, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6521, 26610, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6522, 26614, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6523, 26615, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6524, 26616, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6525, 26617, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6526, 26618, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6527, 26619, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6528, 31991, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6529, 32347, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6530, 32440, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6531, 32441, 'Aripiprazole', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6532, 17, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6533, 18, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6534, 20, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6535, 21, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6536, 22, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6537, 204, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6538, 205, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6539, 925, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6540, 927, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6541, 940, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6542, 943, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6543, 946, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6544, 948, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6545, 950, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6546, 952, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6547, 1766, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6548, 3339, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6549, 10222, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6550, 14308, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6551, 14309, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6552, 14310, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6553, 14311, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6554, 14392, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6555, 14393, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6556, 14394, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6557, 14400, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6558, 14401, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6559, 14404, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6560, 25140, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6561, 26610, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6562, 26614, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6563, 26615, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6564, 26616, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6565, 26617, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6566, 26618, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6567, 26619, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6568, 31991, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6569, 32347, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6570, 32440, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6571, 32441, 'Aripiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6572, 17, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6573, 18, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6574, 20, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6575, 21, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6576, 22, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6577, 204, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6578, 205, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6579, 925, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6580, 927, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6581, 940, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6582, 943, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6583, 946, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6584, 948, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6585, 950, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6586, 952, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6587, 1766, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6588, 3339, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6589, 10222, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6590, 14308, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6591, 14309, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6592, 14310, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6593, 14311, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6594, 14392, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6595, 14393, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6596, 14394, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6597, 14400, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6598, 14401, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6599, 14404, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6600, 25140, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6601, 26610, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6602, 26614, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6603, 26615, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6604, 26616, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6605, 26617, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6606, 26618, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6607, 26619, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6608, 31991, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6609, 32347, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6610, 32440, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6611, 32441, 'Aripiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6612, 17, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6613, 18, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6614, 20, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6615, 21, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6616, 22, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6617, 204, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6618, 205, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6619, 925, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6620, 927, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6621, 940, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6622, 943, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6623, 946, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6624, 948, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6625, 950, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6626, 952, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6627, 1766, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6628, 3339, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6629, 10222, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6630, 14308, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6631, 14309, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6632, 14310, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6633, 14311, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6634, 14392, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6635, 14393, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6636, 14394, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6637, 14400, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6638, 14401, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6639, 14404, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6640, 25140, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6641, 26610, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6642, 26614, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6643, 26615, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6644, 26616, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6645, 26617, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6646, 26618, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6647, 26619, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6648, 31991, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6649, 32347, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6650, 32440, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6651, 32441, 'Aripiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6652, 17, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6653, 18, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6654, 20, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6655, 21, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6656, 22, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6657, 204, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6658, 205, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6659, 925, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6660, 927, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6661, 940, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6662, 943, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6663, 946, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6664, 948, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6665, 950, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6666, 952, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6667, 1766, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6668, 3339, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6669, 10222, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6670, 14308, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6671, 14309, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6672, 14310, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6673, 14311, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6674, 14392, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6675, 14393, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6676, 14394, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6677, 14400, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6678, 14401, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6679, 14404, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6680, 25140, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6681, 26610, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6682, 26614, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6683, 26615, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6684, 26616, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6685, 26617, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6686, 26618, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6687, 26619, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6688, 31991, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6689, 32347, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6690, 32440, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6691, 32441, 'Aripiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6692, 17, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6693, 18, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6694, 20, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6695, 21, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6696, 22, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6697, 204, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6698, 205, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6699, 925, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6700, 927, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6701, 940, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6702, 943, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6703, 946, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6704, 948, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6705, 950, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6706, 952, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6707, 1766, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6708, 3339, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6709, 10222, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6710, 14308, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6711, 14309, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6712, 14310, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6713, 14311, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6714, 14392, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6715, 14393, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6716, 14394, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6717, 14400, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6718, 14401, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6719, 14404, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6720, 25140, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6721, 26610, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6722, 26614, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6723, 26615, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6724, 26616, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6725, 26617, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6726, 26618, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6727, 26619, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6728, 31991, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6729, 32347, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6730, 32440, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6731, 32441, 'Aripiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6732, 17, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6733, 18, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6734, 20, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6735, 21, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6736, 22, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6737, 204, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6738, 205, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6739, 925, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6740, 927, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6741, 940, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6742, 943, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6743, 946, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6744, 948, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6745, 950, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6746, 952, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6747, 1766, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6748, 3339, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6749, 10222, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6750, 14308, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6751, 14309, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6752, 14310, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6753, 14311, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6754, 14392, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6755, 14393, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6756, 14394, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6757, 14400, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6758, 14401, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6759, 14404, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6760, 25140, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6761, 26610, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6762, 26614, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6763, 26615, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6764, 26616, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6765, 26617, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6766, 26618, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6767, 26619, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6768, 31991, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6769, 32347, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6770, 32440, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6771, 32441, 'Aripiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6772, 17, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6773, 18, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6774, 20, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6775, 21, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6776, 22, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6777, 204, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6778, 205, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6779, 925, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6780, 927, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6781, 940, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6782, 943, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6783, 946, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6784, 948, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6785, 950, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6786, 952, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6787, 1766, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6788, 3339, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6789, 10222, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6790, 14308, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6791, 14309, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6792, 14310, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6793, 14311, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6794, 14392, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6795, 14393, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6796, 14394, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6797, 14400, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6798, 14401, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6799, 14404, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6800, 25140, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6801, 26610, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6802, 26614, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6803, 26615, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6804, 26616, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6805, 26617, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6806, 26618, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6807, 26619, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6808, 31991, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6809, 32347, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6810, 32440, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6811, 32441, 'Aripiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6812, 17, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6813, 18, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6814, 20, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6815, 21, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6816, 22, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6817, 204, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6818, 205, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6819, 925, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6820, 927, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6821, 940, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6822, 943, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6823, 946, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6824, 948, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6825, 950, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6826, 952, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6827, 1766, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6828, 3339, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6829, 10222, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6830, 14308, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6831, 14309, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6832, 14310, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6833, 14311, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6834, 14392, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6835, 14393, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6836, 14394, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6837, 14400, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6838, 14401, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6839, 14404, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6840, 25140, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6841, 26610, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6842, 26614, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6843, 26615, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6844, 26616, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6845, 26617, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6846, 26618, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6847, 26619, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6848, 31991, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6849, 32347, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6850, 32440, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6851, 32441, 'Aripiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6852, 17, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6853, 18, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6854, 20, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6855, 21, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6856, 22, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6857, 204, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6858, 205, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6859, 925, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6860, 927, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6861, 940, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6862, 943, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6863, 946, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6864, 948, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6865, 950, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6866, 952, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6867, 1766, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6868, 3339, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6869, 10222, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6870, 14308, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6871, 14309, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6872, 14310, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6873, 14311, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6874, 14392, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6875, 14393, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6876, 14394, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6877, 14400, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6878, 14401, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6879, 14404, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6880, 25140, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6881, 26610, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6882, 26614, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6883, 26615, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6884, 26616, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6885, 26617, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6886, 26618, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6887, 26619, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6888, 31991, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6889, 32347, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6890, 32440, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6891, 32441, 'Aripiprazole', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6892, 17, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6893, 18, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6894, 20, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6895, 21, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6896, 22, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6897, 204, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6898, 205, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6899, 925, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6900, 927, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6901, 940, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6902, 943, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6903, 946, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6904, 948, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6905, 950, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6906, 952, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6907, 1766, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6908, 3339, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6909, 10222, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6910, 14308, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6911, 14309, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6912, 14310, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6913, 14311, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6914, 14392, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6915, 14393, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6916, 14394, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6917, 14400, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6918, 14401, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6919, 14404, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6920, 25140, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6921, 26610, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6922, 26614, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6923, 26615, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6924, 26616, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6925, 26617, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6926, 26618, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6927, 26619, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6928, 31991, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6929, 32347, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6930, 32440, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6931, 32441, 'Aripiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6932, 17, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6933, 18, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6934, 20, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6935, 21, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6936, 22, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6937, 204, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6938, 205, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6939, 925, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6940, 927, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6941, 940, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6942, 943, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6943, 946, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6944, 948, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6945, 950, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6946, 952, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6947, 1766, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6948, 3339, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6949, 10222, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6950, 14308, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6951, 14309, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6952, 14310, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6953, 14311, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6954, 14392, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6955, 14393, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6956, 14394, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6957, 14400, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6958, 14401, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6959, 14404, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6960, 25140, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6961, 26610, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6962, 26614, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6963, 26615, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6964, 26616, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6965, 26617, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6966, 26618, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6967, 26619, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6968, 31991, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6969, 32347, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6970, 32440, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6971, 32441, 'Aripiprazole', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6972, 17, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6973, 18, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6974, 20, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6975, 21, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6976, 22, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6977, 204, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6978, 205, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6979, 925, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6980, 927, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6981, 940, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6982, 943, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6983, 946, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6984, 948, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6985, 950, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6986, 952, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6987, 1766, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6988, 3339, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6989, 10222, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6990, 14308, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6991, 14309, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6992, 14310, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6993, 14311, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6994, 14392, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6995, 14393, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6996, 14394, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6997, 14400, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6998, 14401, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6999, 14404, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7000, 25140, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);